- Home
- SCNI vs INM Comparison
SCNI vs INM Comparison
Compare SCNI & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- INM
- Stock Information
- Founded
- SCNI 2003
- INM 1981
- Country
- SCNI Israel
- INM Canada
- Employees
- SCNI N/A
- INM N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- INM Health Care
- Exchange
- SCNI Nasdaq
- INM Nasdaq
- Market Cap
- SCNI 3.1M
- INM 3.4M
- IPO Year
- SCNI N/A
- INM N/A
- Fundamental
- Price
- SCNI $3.51
- INM $4.95
- Analyst Decision
- SCNI
- INM
- Analyst Count
- SCNI 0
- INM 0
- Target Price
- SCNI N/A
- INM N/A
- AVG Volume (30 Days)
- SCNI 8.1K
- INM 26.6K
- Earning Date
- SCNI 11-22-2024
- INM 02-11-2025
- Dividend Yield
- SCNI N/A
- INM N/A
- EPS Growth
- SCNI N/A
- INM N/A
- EPS
- SCNI 8.20
- INM N/A
- Revenue
- SCNI $452,000.00
- INM $4,960,506.00
- Revenue This Year
- SCNI N/A
- INM N/A
- Revenue Next Year
- SCNI N/A
- INM N/A
- P/E Ratio
- SCNI $0.43
- INM N/A
- Revenue Growth
- SCNI N/A
- INM 5.17
- 52 Week Low
- SCNI $2.23
- INM $2.42
- 52 Week High
- SCNI $8.92
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- SCNI 52.75
- INM 55.90
- Support Level
- SCNI $3.41
- INM $4.07
- Resistance Level
- SCNI $3.80
- INM $5.41
- Average True Range (ATR)
- SCNI 0.18
- INM 0.39
- MACD
- SCNI -0.00
- INM 0.01
- Stochastic Oscillator
- SCNI 36.42
- INM 67.83
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.